Trial Profile
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PICAMEL
- 15 Nov 2023 Status changed from recruiting to completed.
- 04 Jun 2019 Results (n=12) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 25 Jul 2016 Status changed from not yet recruiting to recruiting.